Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C148216> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- NCIT_C148216 IAO_0000115 "A preparation of autologous human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a modified from of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1), in which the intracellular signal domain of PD-1 is transformed to allow for stimulatory signaling but with an intact extracellular ligand binding domain that specifically binds the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), and a modified form of the T-cell inhibitory receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with a transformed intracellular signal domain to allow for stimulatory signaling, which specifically binds the B7 proteins CD80 (B7-1) and CD86 (B7-2), with potential immunostimulating and antineoplastic activities. Usually, ligand binding to PD-1 and CTLA-4 inhibits T-cell activity; however, these modified forms of PD-1 and CTLA-4 promote T-cell stimulatory signaling. Upon administration, the autologous PD-L1/CD80/CD86-targeted CAR-T cells target and bind to PD-L1 expressed on certain tumor cells and to CD80/CD86 expressed on antigen-presenting cells (APCs). This stimulates T-cell activation, T-cell proliferation and enhanced cytokine production, which induces selective toxicity in tumor cells expressing PD-L1. PD-1, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PD-L1 is often overexpressed on tumor cell types and plays a key role in immune evasion. The co-stimulatory molecules CD80 and CD86 play a key role in T-lymphocyte activation upon binding to CD28 upon antigen recognition; however, binding of CD80 and CD86 to wild-type CTLA-4 inhibits T-cell activity and results in T-cell exhaustion." @default.
- NCIT_C148216 NCIT_NHC0 "C148216" @default.
- NCIT_C148216 NCIT_P106 "Cell" @default.
- NCIT_C148216 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C148216 NCIT_P108 "Autologous PD-L1/CD80/CD86-targeted CAR-T Cells" @default.
- NCIT_C148216 NCIT_P208 "CL550853" @default.
- NCIT_C148216 NCIT_P329 "792541" @default.
- NCIT_C148216 NCIT_P330 "792541" @default.
- NCIT_C148216 NCIT_P399 "792541" @default.
- NCIT_C148216 NCIT_R124 NCIT_C17828 @default.
- NCIT_C148216 NCIT_R124 NCIT_C17930 @default.
- NCIT_C148216 NCIT_R124 NCIT_C17937 @default.
- NCIT_C148216 NCIT_R124 NCIT_C18839 @default.
- NCIT_C148216 NCIT_R124 NCIT_C21124 @default.
- NCIT_C148216 NCIT_R124 NCIT_C45548 @default.
- NCIT_C148216 NCIT_R125 NCIT_C17828 @default.
- NCIT_C148216 NCIT_R125 NCIT_C17937 @default.
- NCIT_C148216 NCIT_R125 NCIT_C18095 @default.
- NCIT_C148216 NCIT_R125 NCIT_C18839 @default.
- NCIT_C148216 NCIT_R125 NCIT_C19053 @default.
- NCIT_C148216 NCIT_R125 NCIT_C21124 @default.
- NCIT_C148216 NCIT_R125 NCIT_C26280 @default.
- NCIT_C148216 NCIT_R125 NCIT_C40833 @default.
- NCIT_C148216 NCIT_R125 NCIT_C40912 @default.
- NCIT_C148216 NCIT_R72 NCIT_C104083 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12219 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12476 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12508 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12535 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12542 @default.
- NCIT_C148216 NCIT_R72 NCIT_C12543 @default.
- NCIT_C148216 NCIT_R72 NCIT_C21599 @default.
- NCIT_C148216 NCIT_R72 NCIT_C32725 @default.
- NCIT_C148216 NCIT_R72 NCIT_C33061 @default.
- NCIT_C148216 NCIT_R72 NCIT_C38434 @default.
- NCIT_C148216 NCIT_R72 NCIT_C38439 @default.
- NCIT_C148216 NCIT_R72 NCIT_C39567 @default.
- NCIT_C148216 NCIT_R72 NCIT_C39568 @default.
- NCIT_C148216 normalizedInformationContent "100" @default.
- NCIT_C148216 referenceCount "1" @default.
- NCIT_C148216 hasExactSynonym "Autologous CAR-T Cells Targeting PD-L1 and CD80/CD86" @default.
- NCIT_C148216 hasExactSynonym "Autologous PD-L1/CD80/CD86-targeted CAR-T Cells" @default.
- NCIT_C148216 hasExactSynonym "Z-CTLs" @default.
- NCIT_C148216 hasExactSynonym "Zeushield CTLs" @default.
- NCIT_C148216 hasExactSynonym "Zeushield Cytotoxic T Lymphocytes" @default.
- NCIT_C148216 inSubset NCIT_C128784 @default.
- NCIT_C148216 inSubset NCIT_C176424 @default.
- NCIT_C148216 type Class @default.
- NCIT_C148216 isDefinedBy ncit.owl @default.
- NCIT_C148216 label "Autologous PD-L1/CD80/CD86-targeted CAR-T Cells" @default.
- NCIT_C148216 subClassOf NCIT_C129820 @default.
- NCIT_C148216 subClassOf NCIT_C129821 @default.
- NCIT_C148216 subClassOf NCIT_C129826 @default.
- NCIT_C148216 subClassOf NCIT_C137999 @default.
- NCIT_C148216 subClassOf NCIT_C142078 @default.
- NCIT_C148216 subClassOf NCIT_C148216 @default.
- NCIT_C148216 subClassOf NCIT_C154231 @default.
- NCIT_C148216 subClassOf NCIT_C1908 @default.
- NCIT_C148216 subClassOf NCIT_C1909 @default.
- NCIT_C148216 subClassOf NCIT_C1962 @default.
- NCIT_C148216 subClassOf NCIT_C200766 @default.
- NCIT_C148216 subClassOf NCIT_C274 @default.
- NCIT_C148216 subClassOf NCIT_C28681 @default.
- NCIT_C148216 subClassOf NCIT_C307 @default.
- NCIT_C148216 subClassOf NCIT_C308 @default.